Stock 719 SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Shandong Xinhua Pharmaceutical Company Limited Stock

Equities

719

CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:16 2024-04-24 am EDT 		5-day change 1st Jan Change
5.34 HKD +0.95% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited +0.75% -7.61%
Apr. 11 Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT
Apr. 08 Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application CI

Financials

Sales 2022 7.5B 1.04B 8.11B Sales 2023 8.1B 1.12B 8.76B Capitalization 10.81B 1.49B 11.69B
Net income 2022 411M 56.72M 444M Net income 2023 497M 68.59M 537M EV / Sales 2022 2.12 x
Net Debt 2022 225M 31.07M 243M Net Debt 2023 440M 60.77M 476M EV / Sales 2023 1.39 x
P/E ratio 2022
11.8 x
P/E ratio 2023
7.3 x
Employees 7,104
Yield 2022
2.78%
Yield 2023
4.76%
Free-Float 60.55%
More Fundamentals * Assessed data

Chart Shandong Xinhua Pharmaceutical Company Limited

Dynamic Chart

Latest news about Shandong Xinhua Pharmaceutical Company Limited

Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit MT
Shandong Xinhua Pharmaceutical Proposes New Auditor MT
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34% MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
More news

Press releases Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical : Announcement In Relation To Delay In Despatch Of Circular PU
Shandong Xinhua Pharmaceutical : Appointment of Independent Financial Adviser PU
Shandong Xinhua Pharmaceutical : Overseas Regulatory Announcement PU
Shandong Xinhua Pharmaceutical : (1)Proposed Non-public Issuance of New a Shares;(2)Connected Transaction;(3)Application for Whitewash Waiver;and (4)Proposed Amendments to Articles of Association PU
Shandong Xinhua Pharmaceutical : Unaudited First Quarter Results of 2021 PU
More press releases

Quotes and Performance

1 day+0.95%
1 week+0.75%
Current month-0.74%
1 month+0.19%
3 months-0.37%
6 months+0.19%
Current year-7.61%
More quotes

Highs and lows

1 week
5.22
Extreme 5.22
5.36
1 month
5.22
Extreme 5.22
5.49
Current year
4.80
Extreme 4.8
5.88
1 year
4.80
Extreme 4.8
7.36
3 years
3.61
Extreme 3.61
17.00
5 years
3.32
Extreme 3.32
17.00
10 years
1.98
Extreme 1.9846
17.00
More quotes

Quotes

Date Price Change Volume
24-04-24 5.34 +0.95% 1 130 000
24-04-23 5.29 +0.19% 668,000
24-04-22 5.28 +0.57% 550,000
24-04-19 5.25 -1.13% 590,000
24-04-18 5.31 +0.19% 908,000

Delayed Quote Hong Kong S.E., April 24, 2024 at 04:08 am EDT

More quotes

Company Profile

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
Sector
Pharmaceuticals
Calendar
2024-04-24 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED Stock Shandong Xinhua Pharmaceutical Company Limited
-7.61% 1.17B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.10% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 321B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.47% 217B
NOVARTIS AG Stock Novartis AG
+5.97% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-8.55% 204B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 719 Stock